ES2723797A1 - Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding) - Google Patents

Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding) Download PDF

Info

Publication number
ES2723797A1
ES2723797A1 ES201800061A ES201800061A ES2723797A1 ES 2723797 A1 ES2723797 A1 ES 2723797A1 ES 201800061 A ES201800061 A ES 201800061A ES 201800061 A ES201800061 A ES 201800061A ES 2723797 A1 ES2723797 A1 ES 2723797A1
Authority
ES
Spain
Prior art keywords
left ventricle
gene
patients
translation
methylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ES201800061A
Other languages
Spanish (es)
Inventor
Otero Jose Miguel Rivero
Lletia Esther Rosello
Sanz Manolo Portoles
Cayuela Carolina Gil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES201800061A priority Critical patent/ES2723797A1/en
Publication of ES2723797A1 publication Critical patent/ES2723797A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention refers to a method for diagnosing heart failure of ischemic origin in an individual. We describe a new method for the calculation of the ejection fraction of the left ventricle and the performance of the left ventricle (beat volume) by using the differential methylation of the ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 1- cg11 1898 68- in patients with heart failure of ischemic origin. Our method involves the calculation of the differential methylation of the sites of a certain gene and its use as an instrument of measurement of relationship with an organic function, in this case the ejection fraction and the beat volume, regardless of the relationship obtained using the degree of mRNA expression. We introduce the value of differential methylation as a function regulator by itself, and not only through the down-regulatory action it exerts on gene expression. (Machine-translation by Google Translate, not legally binding)
ES201800061A 2018-02-26 2018-02-26 Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding) Withdrawn ES2723797A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201800061A ES2723797A1 (en) 2018-02-26 2018-02-26 Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201800061A ES2723797A1 (en) 2018-02-26 2018-02-26 Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding)

Publications (1)

Publication Number Publication Date
ES2723797A1 true ES2723797A1 (en) 2019-09-02

Family

ID=67734862

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201800061A Withdrawn ES2723797A1 (en) 2018-02-26 2018-02-26 Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding)

Country Status (1)

Country Link
ES (1) ES2723797A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020003A2 (en) * 2000-09-11 2002-03-14 Merck Patent Gmbh Use of carp inhibitors for the treatment of heart diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020003A2 (en) * 2000-09-11 2002-03-14 Merck Patent Gmbh Use of carp inhibitors for the treatment of heart diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIMURA T. ET AL. Cardiac Ankyrin Repeat Protein Gene (ANKRD1) Mutations in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2009, Vol. 54, Páginas 334-342 página 334, abstract. *
KEMPTON A. ET AL. Altered regulation of cardiac ankyrin repeat protein in heart failure. Heliyon, Enero 2018, Vol. 4, Páginas 1-20 páginas 1-2, abstract; página 9, apartado, 3.3; página 12, apartado, 4. *
LING S. ET AL. Ankyrin Repeat Domain 1 Protein: A Functionally Pleiotropic Protein with Cardiac Biomarker Potential. International Journal of Molecular Sciences, 2017, Vol. 18, Páginas 1362-1385 página 1362, abstract.<br /> *

Similar Documents

Publication Publication Date Title
WO2015176066A3 (en) Lpa-associated protein and rna expression
BR112017010190A2 (en) feature measurement system, measurement method
BR112018073172A8 (en) METHOD FOR IDENTIFICATION OF A TYPE OF WEED, IDENTIFICATION SYSTEM AND COMPUTER PROGRAM PRODUCT
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
BR112018015698A2 (en) ? diagnostic and prognostic methods for cardiovascular disease and events?
PE20180930A1 (en) COMPOSITIONS AND METHODS FOR ACTIVE SURVEILLANCE FOR PROSTATE CANCER
WO2018096375A3 (en) Determination of the receptive status of the endometrium
WO2018199530A3 (en) Diagnostic method for behcet&#39;s disease using metabolome analysis
BR112018011224A2 (en) process of risk assessment for complications in patients with a systemic inflammatory response syndrome (sirs)
WO2018046770A3 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
MX2016001948A (en) Method for diagnosing a malignant lung tumor.
BR112017005474A2 (en) normalization of the response of a fluorescence instrument with the use of spectral response
ES2723797A1 (en) Determination of alterations in the methylation of the ANKYRIN REPEAT-AND SOCS BOX - CONTAINNG PROTEIN 1 gene, as a marker of ventricular dysfunction and the volume of the left ventricle in patients with ischemic heart disease (Machine-translation by Google Translate, not legally binding)
BR112017003608A2 (en) Method for comparative analysis of expression level of target mirna (s), mirna expression analysis device, program (s) for comparative analysis of mirna expression level (s) ), computer readable recording medium and chip for mirna expression analysis?
MX2019014441A (en) A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction.
Güldoğan et al. Correlation between ischemia-modified albumin and Ranson score in acute pancreatitis
WO2018236134A3 (en) Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker
RU2014113841A (en) METHOD FOR EARLY DIAGNOSTICS OF ENDOGENOUS INTOXICATION
MX2017010352A (en) Methods for diagnosing chronic valvular disease.
BR112018075820A2 (en) method for inferring the activity of a transcription factor from a signal transduction pathway in an individual, method for assessing the suitability of a therapy for an individual, system for use in inferring the activity of a transcription factor for a transduction pathway signal in an individual, system for use in assessing the suitability of a therapy for an individual, and computer program
ES2640524A1 (en) Use of tcfl5/cha as a new marker for the prognosis and/or differential diagnosis of acute lymphoblastic leukemias (Machine-translation by Google Translate, not legally binding)
BR112022007705A2 (en) METHOD FOR DIAGNOSIS OF DISEASE RELATED TO HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1)
Freier Role of regulatory T cells and associated chemokines in human gynecological tumors
BR112018009879A2 (en) biomarker of polycystic kidney disease and its uses
Bostner The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations: a crosstalk with potential to predict tamoxifen resistance in breast cancer

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2723797

Country of ref document: ES

Kind code of ref document: A1

Effective date: 20190902

FA2A Application withdrawn

Effective date: 20191217